Aucentra Therapeutics is pleased to announce the appointment of Dr David Fuller as ‘Chief Medical Officer’ and a member of the executive management team commencing 16 November 2022.
Dr Fuller will lead the company’s Australia and global clinical development at a crucial time of significant growth. His extensive experience and background as a biopharmaceutical executive and physician will pave the way with Aucentra Therapeutics lead candidate Auceliciclib Phase II/III clinical trial and progress the pipeline of clinical and pre-clinical drug programs.
During his career, Dr Fuller has led successful major market drug approvals including Moraxen (UK), Busulfex (US Paediatrics and EU Adult indications), Xyrem (US) and Renagel (EU). He has also designed and executed multiple Phase I, II and III studies (US, EU, Asia) for both orphan and non-orphan drug products.
Dr Fuller brings with him international prowess and extensive knowledge of research development & commercialisation of novel pharmaceuticals. His 30 years’ experience spans large, mid, and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.
Recent Comments